Pivotal results set the stage for Japanese escitalopram filing
This article was originally published in Scrip
Executive Summary
Lundbeck has reported positive results from a Japanese pivotal clinical study with the selective serotonin reuptake inhibitor escitalopram, paving the way for a regulatory submission by local licensee Mochida by the end of the first quarter of calendar 2011.